
Regenrate
France · Agri & FoodTech · Undetermined

ZymoChem
United States · Biotech & life sciences · Series A
Compatibility /100
56/100
High potentialWhy talk
- Regenrate likely needs funding — ZymoChem (United States, Series A, $25M raised) can offer investor introductions (inferred from public profile).
- ZymoChem has raised about $25M — investor introductions are realistic.
- Complementary sectors: Agri & FoodTech × Biotech & life sciences — room for a joint offer or co-selling.
Score anatomy
Each segment is what one dimension adds, out of 100.
Score by goal
Dimension by dimension
Needs ↔ offers
22.8 / 35 pts
Value flows both ways.
- Regenrate likely needs funding — ZymoChem (United States, Series A, $25M raised) can offer investor introductions (inferred from public profile).
- ZymoChem likely needs first paying customers — Regenrate can offer access to its customer base (inferred from public profile).
Market bridge
2.5 / 10 pts
Distant markets.
- ZymoChem is based in United States (North America): a landing pad on another continent, both ways.
Customer potential
2.5 / 5 pts
Some customer potential.
- Regenrate has the customers ZymoChem is still looking for — a channel Regenrate can open.
Sector synergy
12.8 / 15 pts
Complementary sectors.
- Complementary sectors: Agri & FoodTech × Biotech & life sciences — room for a joint offer or co-selling.
Stage complementarity
15.7 / 35 pts
Weak stage signal.
- ZymoChem has raised about $25M — investor introductions are realistic.
- Stage not comparable (Undetermined / Series A).
How the score works
Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “Investment”: Needs ↔ offers 35, Market bridge 10, Customer potential 5, Sector synergy 15, Stage complementarity 35. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.
Potential blends compatibility (65%) with the mean global score of both startups (35%): 55/100 — high from 50, medium from 36.